TitleProduct

HER-2 Amplification Probe

  • Price:

    Negotiable

  • minimum:

  • Total supply:

  • Delivery term:

    The date of payment from buyers deliver within days

  • seat:

    Hubei

  • Validity to:

    Long-term effective

  • Last update:

    2018-09-09 22:27

  • Browse the number:

    409

Send an inquiries

Company Profile

Wuhan Healthcare Biotechnology Co.,Ltd

By certification [File Integrity]

Contact:kanglu(Mr.)  

Email:

Telephone:

Phone:

Area:Hubei

Address:Hubei

Website:http://www.health-carebiotech.com/ http://kanglu.golden-sunxj.com/

PRODUCT DETAILS


HER-2 Gene Amplification  Probe


◆Product Advantages

1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour. 

2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.

3.Reproducibility: Different laboratories test results are highly reproducible.


Probe Description

The HER2 gene amplification probe uses orange-red dye to mark the HER-2 gene region .and the green dye to mark the centromeric region of chromosome 17 (CEP17) .The HER2 gene tagged region is located at the 17q12-q21.1, and the CEP17 probe is labeled with a specific alpha satellite sequence.

 

◆Clinical Significance

HER2 gene amplification can be found in many cancers such as breast cancer, hernia, small cell lung cancer, ovarian cancer, prostate cancer, colorectal cancer, salivary glands, etc., and is more common in breast cancer.

Breast cancer is one of the most common malignant tumors in women. The incidence rate accounts for 7-10% of all malignant tumors in the whole body. About 20-35% breast cancer patients have HER2 gene amplification high protein expression. Breast cancer patients are recommended routine detection of HER2 gene status.


◆Size Specifications

 

◆References

Sauter G,et al.J Clin Oncol 27:1323-1333,2009. 

Mass R,et al.Clinical Breast Cancer,Vol 6, No. 3, 240-246, 2005. 

Allison M,Nature Biotechnology 28 (2):117-119, 2010.

Press M,et al,Clinical Cancer Research 2005; 11(18) September 15, 2005

http://www.health-carebiotech.com/